researched and came to a conclusion that this is the next double or triple. a lot of folks that were in amrn will soon take the same path here. congrats to all of you longs. you will hit it big when trial data is released.
Investors were thinking that if trial results were great -- which they were -- that the FDA is going to approve because the previous results were spectacular. I still think AMRN may be a buyout target at say, $22-$25. If not, it will move up a bit when FDA gives its approval. If no approval, then back to $6.00.